HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E4619 Basimglurant Basimglurant(RG7090, CTEP Derivative) is a potent and selective negative allosteric modulator of mGlu5, with a Kd of 1.1 nM, It inhibits the function of mGluR5, thereby regulating glutamatergic neurotransmission. Aug 26 2024
E4879 Laninamivir Laninamivir(R-125489) is a potent inhibitor of influenza neuraminidase(NA)with IC50s of 0.90 nM, 1.83 nM and 3.12 nM for avian H12N5 NA (N5), pH1N1 N1 NA (p09N1) and A/RI/5+/1957 H2N2 N2 (p57N2), respectively. It exhibits long-acting anti-influenza virus activity. Aug 26 2024
E2987 GCN2-IN-1 GCN2-IN-1 (A-92) is a specific and potent active site inhibitor of general control nonderepressible 2 kinase (GCN2) with an IC50 of <0.3 μM. It can be investigated in research related to diseases involving retroviral integration. Aug 26 2024
E4906 Cefadroxil Cefadroxil(BL-S 578) is a first-generation, cephalosporin antibiotic with broad spectrum of anti-bacterial activity. It can be used in the management of infections in the respiratory tract, urinary tract, skin and soft tissues, and bones and joints. Aug 26 2024
E4869 Niraparib hydrochloride Niraparib hydrochloride (MK-4827 hydrochloride) is a potent poly(ADP-ribose)polymerase (PARP) inhibitor with IC50s of 3.8 and 2.1 nM against both the PARP-1 and PARP-2 enzymes, respectively.It inhibits the repair of radiation-induced DNA double-strand breaks, activates apoptosis, and exhibits anti-tumor activity. Aug 26 2024
F0973 DYKDDDDK Tag Mouse mAb DDDDK tag,DYKDDDDK,DYKDDDDK Epitope Tag,DYKDDDDK Tag,OctA-Probe,Flag Aug 25 2024
E4878 Lansoprazole sodium Lansoprazole Sodium, a sodium salt form of Lansoprazole, is an orally active inhibitor of proton pump, preventing the stomach from producing acid. Lansoprazole enhances the expression and transcriptional effectiveness of runt-related transcription factor 2 (Runx2), stimulating osteoprogenitor cell's commitment and differentiation toward their lineage. Aug 22 2024
E1859 FHD-609 FHD-609 acts as a selective inhibitor and degrader of BRD9 protein (bromodomain-containing protein 9). FHD-609 targets ncBAF and can be used in research of various cancers involving mutations in a BAF complex subunit. Aug 22 2024
P1230 Retatrutide Retatrutide (LY3437943) acts as a triple agonist peptide of the glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP-1R) and glucosedependent insulinotropic polypeptide receptor (GIPR). Retatrutide binds to human GCGR, GLP-1R, and GIPR with EC50 values of 5.79, 0.775 nM, and 0.0643, respectively. Retatrutide has the potential for use in research on obesity. Aug 22 2024
E1771 Cycloleucine Cycloleucine is a specific antagonist of NMDA receptor(N-methyl-D-aspartate receptor coupled glycine receptor), with a Ki of 600 μM. Cycloleucine also acts as a specific inhibitor of S-adenosyl-methionine-mediated methylation. Cycloleucine exhibits cytostatic effects. Aug 22 2024
E4887 Dapoxetine Dapoxetine ((S)-(+)-Dapoxetine; LY-210448) is a selective serotonin reuptake inhibitor (SSRI) with oral activity. Dapoxetine is a short-acting SSRI developed specifically for the treatment of premature ejaculation (PE). Aug 22 2024
E4853 Rolapitant hydrochloride hydrate Rolapitant hydrochloride hydrate(SCH619734 hydrochloride hydrate) is a long-acting, extremely selective antagonist of the Nk-1 receptor antagonist (NK-1RA) with antiemetic activity. It significantly penetrates the central nervous system (CNS) and used clinically to prevent chemotherapy-induced nausea and vomiting (CINV) in cancer patients undergoing high and moderate emetogenic chemotherapy. Aug 21 2024
E4867 Omadacycline Omadacycline(Amadacycline) is an oral aminomethylcycline antibacterial antibiotic used to treat moderate-to-severe infections, such as community-acquired pneumonia and acute bacterial skin and skin structure infections caused by susceptible organisms. It inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline has broad-spectrum antibacterial activity and is effective against Gram-positive and Gram-negative aerobic, anaerobic, and atypical bacteria. Aug 21 2024
E4685 Iclepertin Iclepertin(BI-425809) is a potent and selective inhibitor of glycine transporter 1 (GlyT1) that increases glycine levels in the cerebrospinal fluid (CSF). Aug 21 2024
S8687 MPP dihydrochloride Methyl-piperidino-pyrazole (MPP) dihydrochloride is a highly selective antagonist for estrogen receptor alpha (ERα), with an affinity 200 times greater than for estrogen receptor beta (ERβ). It inhibits 17β-estradiol binding to ERα by inducing conformational changes that alter the receptor’s binding site and also increases the energy required for genistein's interaction with ERα. Aug 21 2024
E4610 SMIP34 SMIP34 is a small molecule inhibitor of proline, glutamic acid, and leucine-rich protein 1 (PELP1). It is effective in reducing cell viability, reducing invasion, and inducing apoptosis in Triple-negative breast cancer (TNBC) models. Aug 20 2024
E4655 VT104 VT104 is an inhibitor of TEAD auto-palmitoylation that effectively blocks the palmitoylation of TEAD1 and TEAD3 proteins. It selectively inhibits YAP/TAZ-TEAD-promoted gene transcription and exhibits strong antitumor and anti-proliferative effects. Aug 20 2024
E1964 BMS-986365 BMS-986365 (CC-94676) is a potent and selective, heterobifunctional ligand-directed degrader (LDD) and antagonist of androgen receptor (AR), that effectively targets both wildtype and mutant forms of the androgen receptor (AR) in the cytoplasm and nucleus. It rapidly degrades AR, suppresses AR signaling, and shows promising clinical activity in inhibiting tumor growth in patients with metastatic castration-resistant prostate cancer (mCRPC). Aug 18 2024
E1899 INCB059872 dihydrochloride INCB059872 dihydrochloride is a potent, selective, and irreversible inhibitor of Lysine-Specific Demethylase 1(LSD1). It exhibits potential antineoplastic activity and can be used in acute myeloid leukemia (AML) research. Aug 18 2024
E4877 Lefamulin Lefamulin (BC-3781), is a pleuromutilin antibiotic, inhibits protein synthesis by binding to the peptidyl transferase center of the 50S bacterial ribosome. It is effective against a range of gram-positive pathogens involved in community-acquired bacterial pneumonia (CABP), including Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Legionella pneumophila, Chlamydophila pneumoniae, Staphylococcus aureus (including methicillin-resistant and vancomycin-intermediate strains), and vancomycin-resistant Enterococcus faecium. Aug 18 2024